These results suggest that administering SBRT for the management of inoperable IPNB with mucin secretion not only suppresses mucin secretion and facilitates improvement of jaundice and cholangitis but also exerts an antitumor effect and may prevent future progression to cholangiocarcinoma. Here, MUC5AC is linked to cholangitis.